Story · Medicine & Biotech

Itziar Canamasas: A New Milestone for Boehringer Ingelheim in HER2-Mutant Lung Cancer

1 outlet · first reported by OncoDaily on

Itziar Canamasas, Global Head of Oncology at Boehringer Ingelheim, shared Boehringer Ingelheim’s post on LinkedIn, adding: “Precision oncology is not just about finding the right treatment. It is about making (OncoDaily)

Coverage, in order

  1. OncoDaily obscure
    Itziar Canamasas: A New Milestone for Boehringer Ingelheim in HER2-Mutant Lung Cancer

    Itziar Canamasas, Global Head of Oncology at Boehringer Ingelheim, shared Boehringer Ingelheim’s post on LinkedIn, adding: “Precision oncology is not just about finding the right treatment. It is about making

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.